Deykin Aaron sold $5K of UPB
Deykin Aaron (Chief Medical Officer) sold 895 shares of Upstream Bio, Inc. (UPB) at $6.10 on 2026-06-16.
How this was made
The 30-second read
Why it matters
The filing documents an open-market sale by the company’s Chief Medical Officer, which can slightly influence sentiment but is unlikely to be a standalone catalyst.
Market read
Traders may monitor for additional insider activity, but this specific sale is small and not accompanied by operational or financial updates.
What to watch
Absence of a 10b5-1 plan is notable, but without additional context (e.g., prior sales cadence, compensation structure, or concurrent corporate news) it’s hard to infer directionality.
Background
The article is an SEC Form 4 insider transaction disclosure for Upstream Bio, Inc.
Ticker impact
Upstream Bio CMO Deykin Aaron sold 895 shares in an open-market transaction on 2026-06-16 at $6.10/share, per Form 4.
Likely limited/short-lived impact; watch for follow-on selling or broader news rather than expecting a sustained move from this filing alone.
Form 4 confirms the sale and absence of a 10b5-1 plan, but the dollar value (~$5.5k) is typically not material enough to drive price by itself.
Market effects
No sector-level read-across; this is a single-company insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
The sale could be routine liquidity/portfolio rebalancing by an executive and may not reflect negative fundamentals, especially given the small transaction value.
Key entities
- issuerUpstream Bio, Inc.
Subject of the Form 4 insider sale by its Chief Medical Officer.
- insiderDeykin Aaron
Chief Medical Officer who sold 895 shares on 2026-06-16.
